11:48 AM
 | 
Apr 20, 2018
 |  BC Week In Review  |  Clinical News  |  Regulatory

Opdivo gets Priority Review for third-line SCLC

Bristol-Myers Squibb Co. (NYSE:BMY) said FDA accepted and granted Priority Review to an sBLA for Opdivo nivolumab to treat small cell lung cancer in patients whose disease has progressed after two or more prior therapies. The PDUFA date is Aug. 16.

The sBLA was based on data from the...

Read the full 225 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >